AWAKEN Trademark

Trademark Overview

On Friday, May 19, 2006, a trademark application was filed for AWAKEN with the United States Patent and Trademark Office. The USPTO has given the AWAKEN trademark a serial number of 78887716. The federal status of this trademark filing is REGISTERED AND RENEWED as of Friday, March 5, 2021. This trademark is owned by Bristol-Myers Squibb Company. The AWAKEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for autoimmune diseases, excluding diabetes, infectious diseases and cancer
awaken

General Information

Serial Number78887716
Word MarkAWAKEN
Filing DateFriday, May 19, 2006
Status800 - REGISTERED AND RENEWED
Status DateFriday, March 5, 2021
Registration Number3881765
Registration DateTuesday, November 23, 2010
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2007

Trademark Statements

Goods and ServicesMedical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for autoimmune diseases, excluding diabetes, infectious diseases and cancer

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, May 25, 2006
Primary Code042
First Use Anywhere DateTuesday, April 8, 2008
First Use In Commerce DateTuesday, April 8, 2008

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10154
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 5, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Friday, March 5, 2021REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Friday, March 5, 2021REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, March 2, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, November 20, 2020TEAS SECTION 8 & 9 RECEIVED
Saturday, November 23, 2019COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Monday, October 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 21, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 21, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, February 3, 2017NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Friday, February 3, 2017REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, February 2, 2017CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, November 21, 2016TEAS SECTION 8 & 15 RECEIVED
Tuesday, April 19, 2011ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 19, 2011TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 23, 2010REGISTERED-PRINCIPAL REGISTER
Friday, October 22, 2010NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
Thursday, October 21, 2010LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, October 19, 2010ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 28, 2010STATEMENT OF USE PROCESSING COMPLETE
Friday, September 24, 2010USE AMENDMENT FILED
Friday, September 24, 2010TEAS STATEMENT OF USE RECEIVED
Tuesday, August 10, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Monday, August 9, 2010SOU EXTENSION 5 GRANTED
Wednesday, August 4, 2010SOU EXTENSION 5 FILED
Wednesday, August 4, 2010TEAS EXTENSION RECEIVED
Wednesday, February 24, 2010SOU EXTENSION 4 GRANTED
Thursday, February 18, 2010SOU EXTENSION 4 FILED
Thursday, February 18, 2010TEAS EXTENSION RECEIVED
Thursday, December 17, 2009ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 17, 2009TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, November 27, 2009ASSIGNED TO EXAMINER
Thursday, September 10, 2009SOU EXTENSION 3 GRANTED
Thursday, August 13, 2009SOU EXTENSION 3 FILED
Thursday, September 10, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 13, 2009TEAS EXTENSION RECEIVED
Wednesday, January 28, 2009SOU EXTENSION 2 GRANTED
Wednesday, January 28, 2009SOU EXTENSION 2 FILED
Wednesday, January 28, 2009TEAS EXTENSION RECEIVED
Monday, August 11, 2008SOU EXTENSION 1 GRANTED
Monday, August 11, 2008SOU EXTENSION 1 FILED
Monday, August 11, 2008TEAS EXTENSION RECEIVED
Tuesday, March 4, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 11, 2007PUBLISHED FOR OPPOSITION
Wednesday, November 21, 2007NOTICE OF PUBLICATION
Wednesday, November 7, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, November 1, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 30, 2007EXAMINERS AMENDMENT MAILED
Monday, October 29, 2007EXAMINER'S AMENDMENT ENTERED
Monday, October 29, 2007EXAMINERS AMENDMENT -WRITTEN
Thursday, October 25, 2007SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Thursday, October 25, 2007ASSIGNED TO LIE
Thursday, October 25, 2007ASSIGNED TO EXAMINER
Friday, April 20, 2007REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, October 20, 2006LETTER OF SUSPENSION MAILED
Friday, October 20, 2006SUSPENSION LETTER WRITTEN
Thursday, October 19, 2006ASSIGNED TO EXAMINER
Thursday, May 25, 2006NEW APPLICATION ENTERED

Related Keywords

awaken diseases autoimmune preparations excluding diabetes cancer infectious pharmaceutical relating research